Evidence map›Paper›PMID 35746595›Full record

ArticleViruses2022

A Novel Sphingosine Kinase Inhibitor Suppresses Chikungunya Virus Infection.

Opeoluwa O Oyewole, Kyle Dunnavant, Shaurav Bhattarai, Yugesh Kharel, Kevin R Lynch, Webster L Santos, St Patrick Reid

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Opeoluwa O OyewoleDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-2776-9672
Kyle DunnavantDepartment of Chemistry, Virginia Tech, Blacksburg, VA 24061, USA.
Shaurav BhattaraiDepartment of Cellular and Integrative Physiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-5687-0705
Yugesh KharelDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Kevin R LynchDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Webster L SantosDepartment of Chemistry, Virginia Tech, Blacksburg, VA 24061, USA.
St Patrick ReidDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
University of Nebraska Medical Center · USUniversity of Virginia · USVirginia Tech · US

Funding

MD-PHAR Controlling sphingosine 1-phosphate synthesis and traffickingR01GM121075 · NIGMS · UNIVERSITY OF VIRGINIA · PI LYNCH, KEVIN R., SANTOS, WEBSTER L · 2016 to 2020
$2.1M
NIGMS NIH HHS R01 GM121075
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is a re-emerging arbovirus in the alphavirus genus. Upon infection, it can cause severe joint pain that can last years in some patients, significantly affecting their quality of life. Currently, there are no vaccines or anti-viral therapies available against CHIKV. Its spread to the Americas from the eastern continents has substantially increased the count of the infected by millions. Thus, there is an urgent need to identify therapeutic targets for CHIKV treatment. A potential point of intervention is the sphingosine-1-phosphate (S1P) pathway. Conversion of sphingosine to S1P is catalyzed by Sphingosine kinases (SKs), which we previously showed to be crucial pro-viral host factor during CHIKV infection. In this study, we screened inhibitors of SKs and identified a novel potent inhibitor of CHIKV infection-SLL3071511. We showed that the pre-treatment of cells with SLL3071511 in vitro effectively inhibited CHIKV infection with an EC

Indexed as

Chikungunya FeverChikungunya virusAntiviral AgentsCell LineHumansPhosphotransferases (Alcohol Group Acceptor)Protein Kinase InhibitorsQuality of LifeSphingosineSphingosine KinaseVirus ReplicationAntiviral AgentsPhosphotransferases (Alcohol Group Acceptor)Protein Kinase InhibitorsSphingosineSphingosine KinaseantiviralChikungunya virusdrug discoverySLL3071511 inhibitorSphingosine kinase 2

Identifiers

PMID35746595
PMCPMC9229564
OpenAlexW4281559158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.